Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
September 24, 2021, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”)
appointed Craig Millian as Chief Operating Officer.
Craig
Millian, 53, served as the Company’s Chief Commercial Officer since February 2019, and vacated such office upon appointment as
Chief Operating Officer. Mr. Millian brings 25 years of experience leading commercial organizations for a range of pharmaceutical companies
during all stages of development and commercialization. Prior to joining the Company, Mr. Millian held various leadership positions at
EMD Serono, Inc., including Senior Vice President, Head of U.S. Fertility and Endocrinology from 2012 to 2016, and Senior Vice President,
Head of U.S. Neurology and Immunology from 2016 to 2018. In these roles, he was responsible for leading the strategic direction and driving
operating results for these franchises in the U.S. He oversaw areas of the business including sales, marketing and patient support services.
Previously, Mr. Millian served as Vice President, Commercial at Vertex Pharmaceuticals Inc. (“Vertex”), where he helped design
and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product
pipeline. Prior to Vertex, he held commercial leadership roles at Pfizer Inc. and Sanofi. Mr. Millian holds an MBA from New York University
and a degree in Finance from the University of Pennsylvania.
The
Company entered into an employment agreement with Mr. Millian which became effective April 11, 2020 (the “Employment Agreement”).
The Employment Agreement will be effective for a period of two years. The Employment Agreement provides for Mr. Millian to serve as Chief
Commercial Officer and provides for an annual base salary of $400,000. In addition, pursuant to the Employment Agreement, Mr. Millian
will be eligible to receive an annual bonus, which is targeted at up to 40% of his base salary but which may be adjusted by the Board
based on his individual performance and the Company’s performance as a whole. Pursuant to the terms of the Employment Agreement,
Mr. Millian will be eligible to receive, from time to time, equity awards under the Company’s existing equity incentive plan, or
any other equity incentive plan the Company may adopt in the future, and the payments of such awards, if any, will be determined by the
Board or Compensation Committee of the Board, in their discretion. Mr. Millian is subject to non-compete provisions, which apply during
the term of his employment and for a period of six months from the date of cessation of his employment, subject to the Company providing
as severance ((x) if the Company terminates Mr. Millian’s employment without cause or he terminates his employment for good reason
during the term of the Employment Agreement and (y) he timely executes and does not revoke a general release, which will include a non-compete
covenant, and complies with covenants.) twelve months of his base salary, other than during the three months immediately preceding or
the 12 months immediately following a Change in Control, as defined in the Employment Agreement (the “Change in Control Period”),
in which case it will be increased to eighteen (18) months. Mr. Millian will be subject to non-solicitation provisions, which apply during
the term of his employment and for a period of twelve months from the date of cessation of his employment. In addition, the Employment
Agreement contains customary confidentiality and assignment of inventions provisions. If the Company terminates Mr. Millian’s employment
without cause or he terminates his employment for good reason during the term of the Employment Agreement, other than during the Change
in Control Period, the Company will be required to pay him as severance reimbursement of the cost of COBRA (or to use commercially reasonable
best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for
twelve months, and he may be paid a pro-rated bonus, each subject to his timely execution and non-revocation of a general release, which
will include a non-compete covenant, and continuing compliance with covenants. If the Company terminates Mr. Millian’s employment
without cause or he terminates his employment for good reason during the term of the Employment Agreement, and during the Change in Control
Period, the Company will be required to pay him as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable
best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for
eighteen (18) months, accelerated vesting of all of his outstanding options, restricted stock and other equity incentive awards and his
current year bonus at target levels, each subject to his timely execution and non-revocation of a general release, which will include
a non-compete covenant, and continuing compliance with covenants. Mr. Millian’s severance payments and other applicable payments
and benefits will be subject to reduction to the extent doing so would put him in a better after-tax position after taking into account
any excise tax he may incur under Internal Revenue Code Section 4999 in connection with any change in control of the Company or his subsequent
termination of employment. The Employment Agreement will expire on April 11, 2022.
In
connection with Mr. Millian’s appointment as Chief Operating Officer, the Company entered into an amendment to the Employment Agreement
(the “Amendment”) to change
Mr. Millian’s position
to Chief Operating Officer and to agree that
such change does not constitute Good Reason, as defined in the Employment Agreement.
There are no family
relationships between Mr. Millian and any director or executive officer of the Company.
The
foregoing descriptions of the Employment Agreement and the Amendment do not purport to be complete and are qualified in their entirety
by reference to the full texts of
the Employment Agreement and the Amendment, which are filed as Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed
with the SEC on May 11, 2020 and Exhibit 10.1 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.